Mahmut Gümüş
A5008382382- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- Cancer Risks and Factors
- Inflammatory mediators and NSAID effects
- Gastrointestinal Tumor Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Bladder and Urothelial Cancer Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
Istanbul Medeniyet University
2016-2025
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi
2009-2025
Göztepe Şafak Hastanesi
2025
Università Cattolica del Sacro Cuore
2021-2022
Agostino Gemelli University Polyclinic
2022
Institut Curie
2022
Instituto de Oncología de Rosario
2022
Saitama Medical University
2022
Sheba Medical Center
2022
University of California, Irvine
2022
Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, plus was shown to significantly prolong overall survival among nonsquamous NSCLC.
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with without bevacizumab.
Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) placebo EP for previously untreated extensive-stage (ES) SCLC.Eligible were randomly assigned 1:1 to 200 mg once every 3 weeks or saline up 35 cycles 4 of EP. Primary end points progression-free survival (PFS; RECIST version 1.1, blinded central review) overall (OS) the...
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
No treatment has surpassed platinum-based chemotherapy in improving overall survival patients with previously untreated locally advanced or metastatic urothelial carcinoma. Download a PDF of the Research Summary. We conducted phase 3, global, open-label, randomized trial to compare efficacy and safety enfortumab vedotin pembrolizumab Patients were randomly assigned 1:1 ratio receive 3-week cycles (at dose 1.25 mg per kilogram body weight intravenously on days 1 8) 200 day 1) (enfortumab...
Adiponectin is secreted from adipose tissue and characterized by hyperinsulinemia, which related with obesity. levels are significantly lower in gastric cancer patients than healthy controls. The aim of this study was to investigate the relationship between adiponectin serum, tumor normal some other insulin resistance parameters.A total 35 who had undergone curative gastrectomy standard lymph node dissection were enrolled study. Their serum levels, breast compared.The mean tissue, 48.6±2.9...
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients extensive-stage small lung cancer (SCLC). It remained unknown whether adding a programmed (PD-1) inhibitor provided similar or better benefits SCLC, which would add evidence on efficacy of checkpoint SCLC. Objective To evaluate and adverse event profile PD-1 serplulimab plus compared placebo as Design, Setting, Participants This international,...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We report 5-year efficacy and safety outcomes phase III KEYNOTE-407 study (ClinicalTrials.gov identifier:...
Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) epidermal growth factor receptor (
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg placebo once every 3 weeks up 35 cycles plus...
In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at median follow-up 27 months and key patient-reported outcomes (PROs) are presented.The population included all patients who received least one dose study (n = 5591). Safety...
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
105 Background: Pembro plus pemetrexed and carboplatin resulted in superior objective response rate (ORR), progression-free survival (PFS) overall (OS) for untreated pts with non-sq NSCLC. is active sq NSCLC, so combining chemo a rational next step. Methods: KEYNOTE-407 (NCT02775435) randomized, placebo-controlled, global study of 560 metastatic NSCLC ECOG 0-1. Pts were stratified by type taxane, PD-L1 (TPS <1% vs ≥1%), site (East Asia other). Investigators chose taxane. randomized 1:1 to...
In the phase 3 KEYNOTE-407 study, addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free and objective response rate in patients with previously untreated metastatic squamous non-small-cell lung cancer (NSCLC), little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407.Patients were randomly assigned receive 4 cycles 200 mg or placebo once every weeks plus carboplatin paclitaxel...
The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy or without bevacizumab in patients persistent, recurrent, metastatic cervical cancer. Treatment effects patient subgroups study population are unknown.
Locally advanced colorectal cancers are best treated with multivisceral resections. The aim of this study is to evaluate early and late results after resections.All patients operated for primary cancer between 2001 2010 were -reviewed. These compared within the underwent single organ resections: demographics, tumor procedure related parameters, perioperative results, oncological outcomes 5-year survival.A total 354 (59.6 ± 13.8 years old, 210 [59.3%] males) abstracted. Ninety (25.4%)...